Sector News

Novo Holdings establishes rare bleeding disorder firm Hemab

December 20, 2020
Life sciences

Novo Holdings’ early-stage investment and company creation team Novo Seeds has established a new portfolio company – Hemab – which will focus on the development of bispecific antibodies for rare bleeding disorders.

The company, co-founded by former Novo Nordisk executives Johan Faber and Søren Bjørn, has secured an exclusive license to certain intellectual property to develop a product within haemophilia and other rare bleeding disorders from Novo Nordisk.

Hemab has also scored an exclusive license to Genmab’s bispecific DuoBody platform technology, which will help the company to develop further novel therapies for ultra-rare bleeding disorders.

“We are very pleased to have Novo Seeds on board as investor and partner to accelerate the development of our exciting new technology platform,” said Johan Faber, co-founder and chief executive officer of Hemab.

“We are passionate about developing novel therapies for people with severe bleeding disorders that are in high need for a prophylactic treatment option that is effective, safe and convenient. With the hands-on support of Novo Seeds we have a strong foundation to realize our ambitions for patients with rare bleeding disorders,” he added.

Jørgen Søberg Petersen, Novo Seeds Partner, will join Henmab as chairman and Camilla Petrycer Hansen, Novo Seeds Senior Associate, will also join the board.

In addition, Benny Sørensen, will join the board as an independent non-executive director.

Sørensen currently serves as senior vice president, head of clinical development at Codiak BioSciences.

by Lucy Parsons

Source: pharmatimes.com

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”